Aldevron News
Genprex Taps Aldevron to Enable Full Commercial Scale Plasmid DNA Manufacturing Capabilities
June 16, 2020 / by Aldevron
Genprex, Inc. (NASDAQ: GNPX), is collaborating with Aldevron to secure GMP plasmid DNA manufacturing capacity for Genprex's Oncoprex™ gene therapy portfolio.
The manufacturing program supports upcoming clinical trials, including Oncoprex™ in combination with Tagrisso®, which has received FDA Fast Track
Designation. The collaboration with Aldevron will enable full commercial scale plasmid DNA manufacturing capabilities.
The agreement represents an ongoing dedication to deliver best-in-class gene therapies to patients in need.
The agreement represents an ongoing dedication to deliver best-in-class gene therapies to patients in need.